New growth hormone pen under safety watch in korean kids
NCT ID NCT05509894
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tracks the safety and effectiveness of Ngenla, a growth hormone injection, in over 500 children aged 3 and older with growth hormone deficiency in Korea. Researchers will monitor side effects and growth changes over 6 years during routine medical care. The treatment helps manage the condition but does not cure it, as children need ongoing hormone therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEDIATRIC GROWTH HORMONE DEFICIENCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Seoul, South Korea